Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 5/2011

01-05-2011 | Reviews

Update in HIV Medicine for the Generalist

Authors: Amina A. Chaudhry, MD, MPH, Gail Berkenblit, MD, PhD, Allen L. Gifford, MD, Joseph Cofrancesco Jr, MD, MPH, James Sosman, MD, Lynn E. Sullivan, MD

Published in: Journal of General Internal Medicine | Issue 5/2011

Login to get access

Excerpt

This update examines and summarizes the most recent data on prevention, testing, and treatment of HIV infection for the general internist. Our aims were: (1) to describe the most recent data on HIV prevention; (2) to discuss the recommendations and emerging evidence for routine HIV screening, particularly in community-based settings; (3) to interpret the most recent data on initiation and selection of antiretroviral therapy; and (4) to facilitate the application of these findings to the clinical practice of the generalist. …
Literature
1.
Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes. 2004;11(SUPPL. 1):24A–35A.PubMed
2.
Mosca JD, Bednarik DP, Raj NBK. Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature. 1987;325:67–70.PubMedCrossRef
3.
Kucera LS, Leake E, Iyer N, Raben D, Myrvik QN. Human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) can coinfect and simultaneously replicate in the same human CD4+ cell: effect of coinfection on infectious HSV-2 and HIV-1 replication. AIDS Res Hum Retroviruses. 1990;6:641–647.PubMedCrossRef
4.
Diaz J-J, Duc Dodon M, Schaerer-Uthurralt N, et al. Post-transcriptional transactivation of human retroviral envelope glycoprotein expression by herpes simplex virus Us11 protein. Nature. 1996;379:273–277.PubMedCrossRef
5.
Heng MCY, Heng SY, Allen SG. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet. 1994;343:255–258.PubMedCrossRef
6.
Baeten JM, McClelland RS, Corey L, et al. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis. 2004;189(8):1466–1471 [cited 1 June 2010].PubMedCrossRef
7.
Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. J Am Med Assoc. 1998;280:61–66.CrossRef
8.
Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis. 2002;186:1718–1725.PubMedCrossRef
9.
Mbopi-Keou F, Gresenguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in african women: opportunities for intervention. J Infect Dis. 2000;182:1090–1096.PubMedCrossRef
10.
Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357:1149–1153.PubMedCrossRef
11.
Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS. 2009;23:461–469.PubMedCrossRef
12.
Dunne EF, Whitehead S, Sternberg M, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr. 2008;49:77–83.PubMedCrossRef
13.
Nagot N, Ouédraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med. 2007;356:790–799.PubMedCrossRef
14.
Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis. 2007;196:1500–1508.PubMedCrossRef
15.
Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362:427–439.PubMedCrossRef
16.
17.
Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med. 2005;2:1112–1122.CrossRef
18.
Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643–656.PubMedCrossRef
19.
Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369:657–666.PubMedCrossRef
20.
Wawer MJ, Makumbi F, Kigozi G, et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet. 2009;374:229–237.PubMedCrossRef
21.
Joint United Nations Programme on HIV/AIDS. UNAIDS fact sheet: Sub-saharan Africa. 2007.
22.
Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359:463–472.PubMedCrossRef
23.
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–2220.PubMedCrossRef
24.
Bokhour BG, Solomon JL, Knapp H, Asch SM, Gifford AL. Barriers and facilitators to routine HIV testing in VA primary care. J Gen Intern Med. 2009;24:1109–1114.PubMedCrossRef
25.
Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR.Recommendations and reports: Morbidity and mortality weekly report.Recommendations and reports/Centers for Disease Control. 2006;55:1-17. Available at: http://​www.​cdc.​gov/​mmwr/​preview/​mmwrhtml/​rr5514a1.​htm. Accessed 3 November 2010.
26.
Arbelaez C, Wright EA, Losina E, et al. Emergency provider attitudes and barriers to universal HIV testing in the emergency department. J Emerg Med. 2010 (electronic publication ahead of print). Accessed 1 June 2010.
27.
Myers JJ, Modica C, Dufour M-K, Bernstein C, McNamara K. Routine rapid HIV screening in six community health centers serving populations at risk. J Gen Intern Med. 2009;24:1269–1274.PubMedCrossRef
28.
29.
30.
Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med. 2000;132:306–311.PubMed
31.
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57.PubMedCrossRef
32.
Kelley CF, Kitchen CMR, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009;48:787–794.PubMedCrossRef
33.
Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815–1826.PubMedCrossRef
34.
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. The Lancet. 2009;373:1352-63.
35.
Manson JAE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523–534.PubMedCrossRef
Metadata
Title
Update in HIV Medicine for the Generalist
Authors
Amina A. Chaudhry, MD, MPH
Gail Berkenblit, MD, PhD
Allen L. Gifford, MD
Joseph Cofrancesco Jr, MD, MPH
James Sosman, MD
Lynn E. Sullivan, MD
Publication date
01-05-2011
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 5/2011
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-010-1580-x

Other articles of this Issue 5/2011

Journal of General Internal Medicine 5/2011 Go to the issue

Letters

Groups’ Use of Patient Experience Data

Editorials

Protecting the Public: Is It Time for a Paradigm Shift in Expected Practice Standards?

Original Research

Do Physicians with Self-Reported Non-English Fluency Practice in Linguistically Disadvantaged Communities?

Clinical Practice: Clinical Vignettes

Unilateral Diaphragmatic Paralysis in a Diabetic Patient: A Case of Trepopnea

Original Research

Dosing of Unfractionated Heparin in Obese Patients with Venous Thromboembolism

Original Research

Primary Language, Income and the Intensification of Anti-glycemic Medications in Managed Care: the (TRIAD) Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits